NCT03323619

Brief Summary

Aortic stenosis is a frequent valvulopathy in Europe and North America. It occurs mainly over 65 years (2-7% of the population over 65 years). Treatment of symptomatic stenosis is an indication of aortic valve replacement. For patients with high surgical risk (EuroSCORE II\> 6), TAVI (Transcatheter Aortic Valve Implantation) is recommended. This type of procedure concerns elderly patients (75-80 years on average in the literature) therefore the anesthesia technique must be optimal. The postoperative complications are, on the one hand, well-described surgical complications (Cardiogenic shock, bleeding, rhythm disorders, renal insufficiency) and, on the other hand, those related to anesthesia which are less well characterized. There is no consensus on best anesthesia technique for TAVI procedure managment. Between teams practices are different. It may consist of general anesthesia (GA) or local anesthesia with sedation (LASed). Elderly anesthesia has specific complications, including acute cerebral disturbances (delirium) usually occurring within 24 to 48 hours postoperatively and up to 7 days. It is recommended to screen delirium for patients admitted in intensive care using the CAM-ICU scale. The aim of the study is to observe the impact of the anesthesia technique (GA versus LASed) on delirium in post-operative aortic valve replacement with TAVI procedure

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 24, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 27, 2017

Completed
6 days until next milestone

Study Start

First participant enrolled

November 2, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 2, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2020

Completed
Last Updated

September 6, 2018

Status Verified

September 1, 2018

Enrollment Period

2.8 years

First QC Date

October 24, 2017

Last Update Submit

September 5, 2018

Conditions

Keywords

Transcatheter aortic valve replacementAnesthesia techniqueDelirium

Outcome Measures

Primary Outcomes (1)

  • Delirium

    post-operative delirium after TAVI

    7 days

Secondary Outcomes (1)

  • ICU stay

    30 days

Study Arms (2)

GA

No intervention. General anesthesia is decided by the physicien according to his usual practice

Procedure: anesthesia type

LASed

No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice

Procedure: anesthesia type

Interventions

No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice

GALASed

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patient admitted for TAVI intervention

You may qualify if:

  • Hospital admission for TAVI femoral way
  • Age \> 18 years
  • Psychiatric disease

You may not qualify if:

  • Opposition of the operator (Interventional Cardiologist or Surgeon) to one of the two anesthesia technique
  • Contraindication to local anesthesia with sedation: agitation, delirium, allergy to local anesthetics, risk of inhalation
  • Opposition of the patient to use his data for research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHRU - Hopital de Brabois

Nancy, Lorraine, 54000, France

RECRUITING

MeSH Terms

Conditions

DeliriumPostoperative ComplicationsAortic Valve Disease

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental DisordersPathologic ProcessesHeart Valve DiseasesHeart DiseasesCardiovascular Diseases

Study Officials

  • MATTEI Mathieu, MD

    Central Hospital, Nancy, France

    PRINCIPAL INVESTIGATOR

Central Study Contacts

FRITZ Caroline, MD

CONTACT

MATTEI Mathieu, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 24, 2017

First Posted

October 27, 2017

Study Start

November 2, 2017

Primary Completion

August 2, 2020

Study Completion

November 2, 2020

Last Updated

September 6, 2018

Record last verified: 2018-09

Locations